The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists
Open accessAbstract
It is widely accepted that non-endogenous compounds that target CB(1) and/or CB(2) receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB(1)/CB(2) receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB(2)-selective agonists, peripherally restricted CB(1)/CB(2) receptor agonists and CB(1)/CB(2) antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB(1) and CB(2) receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB(1), non- CB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB(1) and/or CB(2) receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationVanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142 · cited 1×
“Evidence that rimonabant can block TRPV1 channels at concentrations in the low micromolar range has also been obtained from experiments with TRPV1-transfected HEK cells [109], isolated blood vessels [106] and hippocampal neurons [110].”
BackgroundPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Self-citationMustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1
Jordt, S.-E., Bautista, D. M., Chuang, H.-H., McKemy, D. D., Zygmunt, P. M., Högestätt, E. D., Meng, I. D., & Julius, D. (2004) · Nature · doi:10.1038/nature02282 · Cited by 1,899
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 7×
“Conversely, since AM251 seems usually to produce a strong activation of GPR55 [47,52,55,57], it could well be a relatively high-efficacy GPR55 agonist.”
BackgroundInfluentialPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Self-citationTRP channel activation by reversible covalent modification
Hinman, A., Chuang, H.-H., Bautista, D. M., & Julius, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609598103 · Cited by 890
Cannabinoid pharmacology: the first 66 years
Pertwee, R. G. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706406 · Cited by 782
Self-citation2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor
Hanuš, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., & Mechoulam, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061029898 · Cited by 762
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
Self-citationGPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current
Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H.-C., Hille, B., & Mackie, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711278105 · Cited by 712
Pharmacological Actions of Cannabinoids
Pertwee, R. G. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_1 · Cited by 597
Self-citationEvidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain
Breivogel, C. S., Griffin, G., Di Marzo, V., & Martin, B. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.155 · Cited by 541
Pharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Self-citationIdentification of GPR55 as a lysophosphatidylinositol receptor
Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., & Sugiura, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.078 · Cited by 459
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Self-citationEmerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436 · cited 4×
“This is prescribed for the symptomatic relief of neuropathic pain in adults with multiple sclerosis and as an adjunctive analgesic treatment for adult patients with advanced cancer (reviewed in [6]).”
BackgroundInfluentialSelf-citationTRPV1 Channels Mediate Long-Term Depression at Synapses on Hippocampal Interneurons
Gibson, H. E., Edwards, J. G., Page, R. S., Van Hook, M. J., & Kauer, J. A. (2008) · Neuron · doi:10.1016/j.neuron.2007.12.027 · Cited by 388
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors
Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 377
Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G., & Campbell, W. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38289-8 · Cited by 374
Self-citationDe Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agrò, A., & Di Marzo, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008555200 · Cited by 355
In silico patent searching reveals a new cannabinoid receptor
Baker, D., Pryce, G., Davies, W. L., & Hiley, C. R. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.003 · Cited by 348
(R)-Methanandamide: A Chiral Novel Anandamide Possessing Higher Potency and Metabolic Stability
Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G., & Makriyannis, A. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00038a020 · Cited by 346
Self-citationThe putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., & Rogers, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902743106 · Cited by 330
Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
Self-citationThe endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1
Maingret, F. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.47 · Cited by 313
Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., Caldwell, J. S., & Chen, Y. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806516200 · Cited by 311
Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide
Chemin, J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7033 · Cited by 299
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Henstridge, C. M., Balenga, N. A. B., Ford, L. A., Ross, R. A., Waldhoer, M., & Irving, A. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-108670 · Cited by 285
Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands
Kapur, A., Zhao, P., Sharir, H., Bai, Y., Caron, M. G., Barak, L. S., & Abood, M. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.050187 · Cited by 274
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
Johns, D. G., Behm, D. J., Walker, D. J., Ao, Z., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S., Staton, P. C., Green, P., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707419 · Cited by 242
GPR55: a new member of the cannabinoid receptor clan?
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707464 · Cited by 240
Self-citationRoss, R. A., Gibson, T. M., Brockie, H. C., Leslie, M., Pashmi, G., Craib, S. J., Di Marzo, V., & Pertwee, R. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703850 · Cited by 237
Barann, M., Molderings, G., Brüss, M., Bönisch, H., Urban, B. W., & Göthert, M. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704829 · Cited by 215
TRPA1‐mediated responses in trigeminal sensory neurons: interaction between TRPA1 and TRPV1
Salas, M. M., Hargreaves, K. M., & Akopian, A. N. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06702.x · Cited by 211
Dual Effects of Anandamide on NMDA Receptor‐Mediated Responses and Neurotransmission
Hampson, A. J., Bornheim, L. M., Scanziani, M., Yost, C. S., Gray, A. T., Hansen, B. M., Leonoudakis, D. J., & Bickler, P. E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70020671.x · Cited by 208
Berg, A. P., Talley, E. M., Manger, J. P., & Bayliss, D. A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1408-04.2004 · Cited by 206
Pertwee, R. G. (2005) · The AAPS Journal · doi:10.1208/aapsj070364 · Cited by 203
Self-citationIwamura, H., Suzuki, H., Ueda, Y., Kaya, T., & Inaba, T. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38760-9 · Cited by 200
Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol
Ross, H. R., Napier, I., & Connor, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707104200 · Cited by 199
2-Arachidonoyl-sn-glycero-3-phosphoinositol: A Possible Natural Ligand for GPR55
Oka, S., Toshida, T., Maruyama, K., Nakajima, K., Yamashita, A., & Sugiura, T. (2008) · Journal of Biochemistry · doi:10.1093/jb/mvn136 · Cited by 189
Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons
Fan, P. (1995) · Journal of Neurophysiology · doi:10.1152/jn.1995.73.2.907 · Cited by 186
O’Sullivan, S. E., Tarling, E. J., Bennett, A. J., Kendall, D. A., & Randall, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.121 · Cited by 183
Thomas, A., Stevenson, L. A., Wease, K. N., Price, M. R., Baillie, G., Ross, R. A., & Pertwee, R. G. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706414 · Cited by 179
Self-citationActivation Properties of Heterologously Expressed Mammalian TRPV2
Neeper, M. P., Liu, Y., Hutchinson, T. L., Wang, Y., Flores, C. M., & Qin, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608287200 · Cited by 179
Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P., & Kaminski, N. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019117 · Cited by 176
Hejazi, N. S., Zhou, C., Öz, M., Sun, H., Ye, J. H., & Zhang, L. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.019174 · Cited by 175
Receptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids
Oz, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.009 · Cited by 165
Price, T. J., Patwardhan, A. M., Akopian, A. N., Hargreaves, K., & Flores, C. M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705711 · Cited by 165
The expanding field of cannabimimetic and related lipid mediators
Bradshaw, H. B., & Walker, J. M. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706093 · Cited by 163
Sink, K. S., McLaughlin, P. J., Wood, J. A. T., Brown, C., Fan, P., Vemuri, V. K., Pang, Y., Olzewska, T., Thakur, G. A., Makriyannis, A., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301476 · Cited by 161
Hurst, D. P., Lynch, D. L., Barnett-Norris, J., Hyatt, S. M., Seltzman, H. H., Zhong, M., Song, Z.-H., Nie, J., Lewis, D., & Reggio, P. H. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.6.1274 · Cited by 160
Savinainen, J. R., Järvinen, T., Laine, K., & Laitinen, J. T. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704297 · Cited by 159
Interactions between synthetic vanilloids and the endogenous cannabinoid system
Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, L., Pertwee, R., & De Petrocellis, L. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01175-2 · Cited by 158
Self-citationShen, M., & Thayer, S. A. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01195-5 · Cited by 146
Cannabinoids and Multiple Sclerosis
Pertwee, R. G. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0005-2 · Cited by 142
Self-citationCannabinoids Desensitize Capsaicin and Mustard Oil Responses in Sensory Neurons via TRPA1 Activation
Akopian, A. N., Ruparel, N. B., Patwardhan, A. M., & Hargreaves, K. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1565-06.2008 · Cited by 142
Anandamide, an Endogenous Cannabinoid, Inhibits Shaker-related Voltage-gated K+ Channels
POLING, J. S., Rogawski, M. A., Salem, N., & Vicini, S. (1996) · Neuropharmacology · doi:10.1016/0028-3908(96)00130-x · Cited by 132
Linden, A.-M., Sandu, C., Aller, M. I., Vekovischeva, O. Y., Rosenberg, P. H., Wisden, W., & Korpi, E. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129544 · Cited by 131
Zygmunt, P. M., Andersson, D. A., & Högestätt, E. D. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04720.2002 · Cited by 128
Biology and therapeutic potential of cannabinoid CB2receptor inverse agonists
Lunn, C. A., Reich, E., Fine, J. S., Lavey, B. J., Kozlowski, J. A., Hipkin, R. W., Lundell, D. J., & Bober, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707480 · Cited by 120
Cheer, J. F., Cadogan, A. K., Marsden, C. A., Fone, K. C. F., & Kendal, D. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00208-1 · Cited by 120
Mestre, L., Docagne, F., Correa, F., Loría, F., Hernangómez, M., Borrell, J. I., & Guaza, C. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.10.015 · Cited by 116
Savinainen, J. R., Saario, S. M., Niemi, R., Järvinen, T., & Laitinen, J. T. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705577 · Cited by 112
Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain
Nicholson, R. A., Liao, C., Zheng, J., David, L. S., Coyne, L., Errington, A. C., Singh, G., & Lees, G. V. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02808-7 · Cited by 107
Govaerts, S. J., Hermans, E., & Lambert, D. M. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.07.013 · Cited by 107
Pertwee, R. G., Thomas, A., Stevenson, L. A., Ross, R. A., Varvel, S. A., Lichtman, A. H., Martin, B. R., & Razdan, R. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707124 · Cited by 105
Self-citationFong, T. M., Guan, X.-M., Marsh, D. J., Shen, C.-P., Stribling, D. S., Rosko, K., Lao, J. Z., Yu, H., Feng, Y., Xiao, J. C., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.118737 · Cited by 105
A neutral CB1 receptor antagonist reduces weight gain in rat
Chambers, A. P., Vemuri, K. V., Peng, Y., Wood, J. T., Olszewska, T., Pittman, Q. J., Makriyannis, A., & Sharkey, K. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00663.2007 · Cited by 105
Modulation of rat brain opioid receptors by cannabinoids.
VAYSSE, P. J. ‐., Gardner, E. L., & Zukin, R. S. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00276-9 · Cited by 103
Linden, A.-M., Aller, M. I., Leppä, E., Vekovischeva, O. Y., Aitta‐aho, T., Veale, E. L., Mathie, A. A., Rosenberg, P. H., Wisden, W., & Korpi, E. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098525 · Cited by 101
Glycine Receptors in CNS Neurons as a Target for Nonretrograde Action of Cannabinoids
Lozovaya, N., Yatsenko, N., Beketov, A., Tsintsadze, T. S., & Burnashev, N. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0977-05.2005 · Cited by 99
Ruiu, S., Pinna, G. A., Marchese, G., Mussinu, J., Saba, P., Tambaro, S., Casti, P., Vargiu, R., & Pani, L. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049924 · Cited by 93
Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Huffman, J. W., & Marriott, K. C. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783498014 · Cited by 92
Ralevic, V., Kendall, D. A., Randall, M. D., Zygmunt, P. M., Movahed, P., & Högestätt, E. D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703456 · Cited by 88
Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine
Yang, Z., Aubrey, K. R., Alroy, I., Harvey, R. J., Vandenberg, R. J., & Lynch, J. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.037 · Cited by 87
Cavanaugh, E. J., Simkin, D., & Kim, D. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.048 · Cited by 82
Lee, H., Choi, E., & Pak, C. S. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788897844 · Cited by 80
Poso, A., & Huffman, J. W. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707567 · Cited by 74
Chemical Determinants Involved in Anandamide-induced Inhibition of T-type Calcium Channels
Chemin, J., Nargeot, J., & Lory, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m610033200 · Cited by 72
Öz, M., Zhang, L., Ravindran, A., Morales, M., & Lupica, C. R. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067751 · Cited by 71
Giuliano, M., Pellerito, O., Portanova, P., Calvaruso, G., Santulli, A., BLASIO, A. D., Vento, R., & Tesoriere, G. (2008) · Biochimie · doi:10.1016/j.biochi.2008.11.003 · Cited by 68
Multiple actions of anandamide on neonatal rat cultured sensory neurones
Evans, R. M., Scott, R. H., & Ross, R. A. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705723 · Cited by 55
Molderings, G. J., Likungu, J., & Göther, M. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s002109900043 · Cited by 53
Eichele, K., Ramer, R., & Hinz, B. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9748-3 · Cited by 52
Öz, M., Tchugunova, Y. B., & Dunn, S. M. J. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00396-4 · Cited by 51
Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors
Christopoulos, A., & Wilson, K. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02825-6 · Cited by 48
Price, T. J., Patwardhan, A. M., Akopian, A. N., Hargreaves, K., & Flores, C. M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705778 · Cited by 46
Savinainen, J. R., Kokkola, T., Salo‐Ahen, O. M. H., Poso, A., Järvinen, T., & Laitinen, J. T. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706230 · Cited by 45
Maekawa, T., Nojima, H., Kuraishi, Y., & Aisaka, K. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.040 · Cited by 44
Design, Synthesis, and Binding Studies of New Potent Ligands of Cannabinoid Receptors
Brizzi, A., Brizzi, V., Cascio, M. G., Bisogno, T., Sirianni, R., & Marzo, V. D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0501533 · Cited by 44
Molderings, G. J., Bönisch, H., Hammermann, R., Göthert, M., & Brüss, M. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00076-6 · Cited by 44
Öz, M., Tchugunova, Y. B., & Dinç, M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.052 · Cited by 44
Sink, K. S., Vemuri, K. V., Wood, J. T., Makriyannis, A., & Salamone, J. D. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.013 · Cited by 43
den Bossche, I. V., & Vanheel, B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703521 · Cited by 43
Ooms, F., Wouters, J., Oscari, O., Happaerts, T., Bouchard, G., Carrupt, P., Testa, B., & Lambert, D. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010896y · Cited by 43
Veale, E. L., Buswell, R. L., Clarke, C. E., & Mathie, A. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707436 · Cited by 42
Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids
Sade, H., Muraki, K., Ohya, S., Hatano, N., & Imaizumi, Y. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00482.2004 · Cited by 42
Contribution of CB1 blockade to the management of high-risk abdominal obesity
Després, J., Lemieux, I., & Alméras, N. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803278 · Cited by 40
Çınar, R., & Szűcs, M. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.152710 · Cited by 37
Δ9-Tetrahydrocannabinol-induced changes in β-adrenergic receptor binding in mouse cerebral cortex
Hillard, C. J., & Bloom, A. S. (1982) · Brain Research · doi:10.1016/0006-8993(82)91016-2 · Cited by 34
Cannabinoid CB1receptor antagonists in therapeutic and structural perspectives
Lange, J. H. M., & Kruse, C. G. (2008) · The Chemical Record · doi:10.1002/tcr.20147 · Cited by 32
Modulation of Glycine Receptor Function by the Synthetic Cannabinoid HU210
Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., Karst, M., Dengler, R., Haeseler, G., & Ahrens, J. (2009) · Pharmacology · doi:10.1159/000209291 · Cited by 31
Cascio, M. G., Bisogno, T., Palazzo, E., Thomas, A., van der Stelt, M., Brizzi, A., de Novellis, V., Marabese, I., Ross, R. A., van de Doelen, T., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706888 · Cited by 22
Self-citationLiao, C., Zheng, J., David, L. S., & Nicholson, R. A. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.pto940204.x · Cited by 20
Duan, Y., Liao, C., Jain, S. A., & Nicholson, R. A. (2008) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2008.06.002 · Cited by 11
Effects of WIN55,212-2 on voltage-gated sodium channels in trigeminal ganglion neurons of rats
Fu, H., Xiao, J. M., Cao, X., Ming, Z. Y., & Liu, L. J. (2008) · Neurological Research · doi:10.1179/016164107x228642 · Cited by 9
Tambaro, S., Mongeau, R., Dessì, C., Pani, L., & Ruiu, S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.09.058 · Cited by 7
Cited by
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 709
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393
Self-citationIannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Metadata
- Authors
- Pertwee, R.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-05-01
- Volume
- 17
- Issue
- 14
- Pages
- 1360-1381
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2007485514
- Cited by
- 335
- References
- 110
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.